NATURE’S FIRST RESPONDER™
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System
N-803 is an IL-15RαFc Superagonist, a proprietary therapeutic cytokine designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells; Aldoxorubicin (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Both agents are in late-stage clinical development by our affiliate, ImmunityBio, which has exclusive, worldwide rights to the agents. Avelumab is an FDA approved checkpoint inhibitor marketed by Pfizer.
1. Program owned by NantKwest and subject to binding term sheet with ImmunityBio
2. Program owned by ImmunityBio and subject to a binding term sheet for joint development collaboration with NK
To learn more about the Nant Cancer Vaccine
To learn more about our clinical trials